Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan
- PMID: 18053454
- DOI: 10.1016/S0025-6196(11)61090-2
Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan
Abstract
Objective: To assess the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in a large Japanese population.
Participants and methods: From October 1, 1988, to March 31, 2004, a total of 52,802 (of 71,675) Japanese survivors of the atomic bomb explosion in Nagasaki City, Japan, were screened for M protein. The youngest participant was 42.3 years as of October 1, 1988. A 2-step screening was performed with a serum protein electrophoresis followed by immunoelectrophoresis and a quantitative determination of serum concentration of immunoglobulins. Twenty-one patients who were diagnosed for the first time at the time of screening as having multiple myeloma and Waldenström macroglobulinemia were excluded from analyses. Age- and sex-specific prevalence rates of MGUS were calculated.
Results: Monoclonal gammopathy of undetermined significance was identified in 1088 of the 52,781 study participants. The overall prevalence of MGUS was 2.1% (95% confidence interval [CI], 1.9%-2.2%) in the total population screened and 2.4% (95% CI, 2.0%-2.6%) in those 50 years or older. The prevalence was significantly higher in men than in women (2.8% vs 1.6%; age-adjusted odds ratio, 2.0; 95% CI, 1.8-2.3; P less than .001). In both sexes, the prevalence rose with increasing age from 1.0% in participants aged 42 to 49 years, 1.9% in those 50 to 59 years, 2.6% in those 60 to 69 years, and 3.0% in those 70 to 79 years, to 4.4% in those 80 years and older. The heavy chain isotypes of immunoglobulin were IgG in 73.6% of patients, IgA in 17.7%, IgM in 7.5%, and oligoclonal gammopathies in 1.1%.
Conclusion: The prevalence of MGUS is lower in this Japanese population than that reported in Western countries among people older than 60 years, especially among women.
Comment in
-
Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies.Mayo Clin Proc. 2007 Dec;82(12):1457-9. doi: 10.1016/S0025-6196(11)61086-0. Mayo Clin Proc. 2007. PMID: 18053450 No abstract available.
-
Genetic predisposition for monoclonal gammopathy of undetermined significance.Mayo Clin Proc. 2008 May;83(5):601-2; author reply 602-3. doi: 10.4065/83.5.601-a. Mayo Clin Proc. 2008. PMID: 18452695 No abstract available.
Similar articles
-
Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors.Blood. 2009 Feb 19;113(8):1639-50. doi: 10.1182/blood-2008-05-159665. Epub 2008 Oct 10. Blood. 2009. PMID: 18849487
-
Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):18-20. doi: 10.1016/j.clml.2013.12.010. Epub 2013 Dec 19. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24461807
-
Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e71-7. doi: 10.1016/j.clml.2016.02.034. Epub 2016 Feb 27. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27013181
-
Monoclonal gammopathies of undetermined significance: a review.Immunol Rev. 2003 Aug;194:112-39. doi: 10.1034/j.1600-065x.2003.00056.x. Immunol Rev. 2003. PMID: 12846812 Review.
-
Monoclonal gammopathy of undetermined significance.Clin Lymphoma Myeloma. 2005 Sep;6(2):102-14. doi: 10.3816/CLM.2005.n.036. Clin Lymphoma Myeloma. 2005. PMID: 16231848 Review.
Cited by
-
The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease.Front Oncol. 2024 Oct 14;14:1461128. doi: 10.3389/fonc.2024.1461128. eCollection 2024. Front Oncol. 2024. PMID: 39469644 Free PMC article. Review.
-
Elucidating disparities across racial and ethnic groups in multiple myeloma patients.Int J Hematol. 2012 Apr;95(4):453-4. doi: 10.1007/s12185-012-1040-y. Epub 2012 Mar 9. Int J Hematol. 2012. PMID: 22403056 No abstract available.
-
Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).Oncology (Williston Park). 2011 Jun;25(7):578-86. Oncology (Williston Park). 2011. PMID: 21888255 Free PMC article. Review.
-
Monoclonal gammopathy in the setting of Pyoderma gangrenosum.Arch Dermatol Res. 2024 May 25;316(6):268. doi: 10.1007/s00403-024-03098-7. Arch Dermatol Res. 2024. PMID: 38795175
-
Prevention of progression in monoclonal gammopathy of undetermined significance.Clin Cancer Res. 2009 Sep 15;15(18):5606-8. doi: 10.1158/1078-0432.CCR-09-1575. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737944 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous